Prognostic role of macrophage migration inhibitory factor in patients with myocardial infarction with ST-segment elevation after percutaneous coronary intervention

Authors

  • Mykola Kopytsya Government Institution “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” Liubovi Maloy ave., 2-a, Kharkiv, Ukraine, 61039, Ukraine https://orcid.org/0000-0003-4779-7347
  • Irina Vishnevskaya Government Institution “L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” Liubovi Maloy ave., 2-a, Kharkiv, Ukraine, 61039, Ukraine https://orcid.org/0000-0002-6914-3144
  • Tatyana Storozhenko Government Institution “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” Liubovi Maloy ave., 2-a, Kharkiv, Ukraine, 61039, Ukraine https://orcid.org/0000-0002-9158-2012

DOI:

https://doi.org/10.15587/2519-4798.2019.185453

Keywords:

macrophage migration inhibitory factor, acute myocardial infarction, prediction, biomarkers

Abstract

The aim of the study was to determine the prediction role of MIF in development of STEMI complications within 6 months after the event.

Materials and methods. The study included 45 people with confirmed myocardial infarction with ST segment elevation (STEMI) and successful restoration of blood flow - TIMI-III. The control group - 12 healthy volunteers. All patients underwent baseline investigation. The level of myocardial damage biomarkers MIF and troponin were determined before percutaneous coronary intervention (PCI), then within 24 hours. The pro-inflammatory CRP biomarker was determined before PCI and 5-7 days after the development of the coronary event. The patient follow-up period was 6 months, during which 8 patients reached the endpoint.

Results and discussion. Statistically significant increase of MIF levels in STEMI patients was defined relative to the control group. During the observation period 19% of patients reached the endpoint. The MIFІ level significantly correlated with complications in the acute period of myocardial infarction, the class of acute heart failure according to Killip, with troponin levels, with active smoking, MIFII was correlated with stable angina pectoris before the index event, the size of the left atrium and the mass of the left ventricular myocardium. Assessment of blood glucose in with the MIFII was significant in predicting the development of an adverse outcome, in comparison with a separate biomarker definition, the diagnostic efficiency of the model was 88%.

Conclusions. An early increase of MIF level was associated with an adverse course of the disease. Our prognostic model significantly improved the prediction of the risk of complications after STEMI

Author Biographies

Mykola Kopytsya, Government Institution “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” Liubovi Maloy ave., 2-a, Kharkiv, Ukraine, 61039

MD, Head of Department

Department of Prevention and Treatment of Emergency Conditions

Irina Vishnevskaya, Government Institution “L.T.Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” Liubovi Maloy ave., 2-a, Kharkiv, Ukraine, 61039

PhD, Senior Researcher

Department of Prevention and Treatment of Emergency Conditions

Tatyana Storozhenko, Government Institution “L. T. Malaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine” Liubovi Maloy ave., 2-a, Kharkiv, Ukraine, 61039

Junior Researcher

Department of Prevention and Treatment of Emergency Conditions

References

  1. Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H. et. al. (2017). 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 39 (2), 119–177. doi: http://doi.org/10.1093/eurheartj/ehx393
  2. Fan, F., Fang, L., Moore, X., Xie, X., Du, X., White, D. A. et. al. (2016). Plasma Macrophage Migration Inhibitor Factor Is Elevated in Response to Myocardial Ischemia. Journal of the American Heart Association, 5 (7). doi: http://doi.org/10.1161/jaha.115.003128
  3. Chan, W., White, D. A., Wang, X., Bai, R., Liu, Y., Yu, H. et. al. (2013). Macrophage Migration Inhibitory Factor for the Early Prediction of Infarct Size. Journal of the American Heart Association, 2 (5). doi: http://doi.org/10.1161/jaha.113.000226
  4. Yla-Herttuala, S., Bentzon, J. F., Daemen, M., Falk, E., Garcia-Garcia, H. M. et. al. (2013). Stabilization of atherosclerotic plaques: an update. European Heart Journal, 34 (42), 3251–3258. doi: http://doi.org/10.1093/eurheartj/eht301
  5. Zhou, B., Ren, C., Zu, L., Zheng, L., Guo, L., Gao, W. (2016). Elevated plasma migration inhibitory factor in hypertension–hyperlipidemia patients correlates with impaired endothelial function. Medicine, 95 (43), e5207. doi: http://doi.org/10.1097/md.0000000000005207
  6. Takahashi, M. (2001). Macrophage migration inhibitory factor as a redox-sensitive cytokine in cardiac myocytes. Cardiovascular Research, 52 (3), 438–445. doi: http://doi.org/10.1016/s0008-6363(01)00408-4
  7. Yu, H., Wang, X., Deng, X., Zhang, Y., Gao, W. (2019). Correlation between Plasma Macrophage Migration Inhibitory Factor Levels and Long-Term Prognosis in Patients with Acute Myocardial Infarction Complicated with Diabetes. Mediators of Inflammation, 2019, 1–9. doi: http://doi.org/10.1155/2019/8276180
  8. Zhao, Q., Men, L., Li, X.-M., Liu, F., Shan, C.-F., Zhou, X.-R. et. al. (2019). Circulating MIF Levels Predict Clinical Outcomes in Patients With ST-Elevation Myocardial Infarction After Percutaneous Coronary Intervention. Canadian Journal of Cardiology, 35 (10), 1366–1376. doi: http://doi.org/10.1016/j.cjca.2019.04.028
  9. Deng, F., Zhao, Q., Deng, Y., Wu, Y., Zhou, D., Liu, W. et. al. (2018). Prognostic significance and dynamic change of plasma macrophage migration inhibitory factor in patients with acute ST-elevation myocardial infarction. Medicine, 97 (43), e12991. doi: http://doi.org/10.1097/md.0000000000012991
  10. Müller, I. I., Müller, K. A. L., Schönleber, H., Karathanos, A., Schneider, M., Jorbenadze, R. et. al. (2012). Macrophage Migration Inhibitory Factor Is Enhanced in Acute Coronary Syndromes and Is Associated with the Inflammatory Response. PLoS ONE, 7 (6), e38376. doi: http://doi.org/10.1371/journal.pone.0038376
  11. Miller, E. J., Li, J., Leng, L., McDonald, C., Atsumi, T., Bucala, R., Young, L. H. (2008). Macrophage migration inhibitory factor stimulates AMP-activated protein kinase in the ischaemic heart. Nature, 451 (7178), 578–582. doi: http://doi.org/10.1038/nature06504
  12. White, D. A., Su, Y., Kanellakis, P., Kiriazis, H., Morand, E. F., Bucala, R. et. al. (2014). Differential roles of cardiac and leukocyte derived macrophage migration inhibitory factor in inflammatory responses and cardiac remodelling post myocardial infarction. Journal of Molecular and Cellular Cardiology, 69, 32–42. doi: http://doi.org/10.1016/j.yjmcc.2014.01.015
  13. Dayawansa, N. H., Gao, X.-M., White, D. A., Dart, A. M., Du, X.-J. (2014). Role of MIF in myocardial ischaemia and infarction: insight from recent clinical and experimental findings. Clinical Science, 127 (3), 149–161. doi: http://doi.org/10.1042/cs20130828
  14. White, D. A., Fang, L., Chan, W., Morand, E. F., Kiriazis, H., Duffy, S. J. et. al. (2013). Pro-Inflammatory Action of MIF in Acute Myocardial Infarction via Activation of Peripheral Blood Mononuclear Cells. PLoS ONE, 8 (10), e76206. doi: http://doi.org/10.1371/journal.pone.0076206
  15. Wang, J., Tong, C., Yan, X., Yeung, E., Gandavadi, S., Hare, A. A. et. al. (2013). Limiting Cardiac Ischemic Injury by Pharmacological Augmentation of Macrophage Migration Inhibitory Factor–AMP-Activated Protein Kinase Signal Transduction. Circulation, 128 (3), 225–236. doi: http://doi.org/10.1161/circulationaha.112.000862

Downloads

Published

2019-12-11

How to Cite

Kopytsya, M., Vishnevskaya, I., & Storozhenko, T. (2019). Prognostic role of macrophage migration inhibitory factor in patients with myocardial infarction with ST-segment elevation after percutaneous coronary intervention. ScienceRise: Medical Science, (6 (33), 20–25. https://doi.org/10.15587/2519-4798.2019.185453

Issue

No. 6 (33) (2019)

Section

Medical Science

License

Copyright (c) 2019 Mykola Kopytsya, Irina Vishnevskaya, Tatyana Storozhenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.